Chembio Wins $13.2M US BARDA Contract To Develop POC Zika Tests
HHS and its subagency Biomedical Advanced Research and Development Authority (BARDA) has put together additional funding to award Chembio Diagnostic Systems $13.2m to develop and commercialize the firm's rapid point-of-care Zika test, a mere two weeks after the agency said it only had enough funds for Zika vaccine development.
You may also be interested in...
The US Biomedical Advanced Research and Development Authority (BARDA) recently granted $4.1m to Hologic to advance development of a blood screen to detect Zika in the blood supply. Also, lawmakers are asking more questions about readiness in the US for detecting emerging infectious diseases and bioterrorism-related toxins.
Emergency funding to battle the summer's mosquito-borne Zika threat is trapped in a military/VA spending bill. Conferees must find a compromise between the House's $622m bid and the Senate's $1.1b offer in the thin stretch of time when both chambers will be session before they adjourn on July 15. In the interim, FDA has authorized more Zika tests.
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.